Primary VHH

Primary VHH antibodies, also known as nanobodies, , offer significant advantages over traditional antibodies. These single-domain antibodies, derived from camelid heavy-chain antibodies, directly target specific antigens or proteins associated with disease, paving the way for novel and effective therapies. The success of nanobody-based therapeutics is underscored by the approval of drugs like Caplacizumab (Cablivi®), used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).

Unlike conventional antibodies, which are composed of heavy and light chains, nanobodies consist of a single variable domain (VHH). This compact size (approximately 15 kDa) confers several key benefits for therapeutic applications:

• Enhanced Tissue Penetration: Their small size allows for deeper and more efficient penetration into tissues, including solid tumors and other difficult-to-reach targets.
• High Stability and Solubility: Nanobodies exhibit remarkable stability under various conditions, including high temperatures and extreme pH levels, and maintain high solubility, which is crucial for formulation and delivery.
• Rapid Clearance and Tunable Pharmacokinetics: Their small size allows for rapid clearance from the bloodstream, which can be advantageous for certain therapeutic applications. Additionally, their pharmacokinetics can be easily tuned through modifications.
• Ease of Engineering and Production: Nanobodies can be easily engineered and produced in microbial systems, enabling rapid development and cost-effective manufacturing.
• Low Immunogenicity: Their high sequence homology to human heavy-chain antibodies minimizes the risk of triggering an immune response.
• Multivalent and Multispecific Formats: Nanobodies can be easily linked together to create multivalent or multispecific constructs, enabling simultaneous targeting of multiple epitopes or targets, further expanding their therapeutic potential.

These properties, demonstrated by the success of approved nanobody drugs, make primary VHH antibodies ideal candidates for a wide range of therapeutic applications, including cancer, autoimmune diseases, infectious diseases, and inflammatory conditions. By directly targeting disease-associated antigens with high precision and efficacy, nanobodies hold immense promise for improving patient outcomes and revolutionizing the landscape of modern medicine.

At Echo Bio, we offer a comprehensive portfolio of VHH antibodies (Research Use Only), targeting a wide range of diseases, including cancers, autoimmune disorders, infections, and more, by targeting specific proteins or markers on cells or tissues such as CD13, IL6, PTH and so on. 

Need a custom solution or help? Contact us today!
Email: info@echobiosystems.com 
Phone: 1-646-351-4812